Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5272258 | 0.89 | HSD11B1 (0.43) | — | |
| SCHEMBL6164790 | 0.89 | PTGS2 (0.51) | PTGS2 | |
| SCHEMBL6168650 | 0.88 | — | — | |
| SCHEMBL5865424 | 0.87 | — | — | |
| SCHEMBL27611197 | 0.87 | — | — | |
| SCHEMBL27630111 | 0.87 | — | — | |
| SCHEMBL5271166 | 0.87 | — | — | |
| SCHEMBL5865460 | 0.87 | — | — | |
| SCHEMBL5280363 | 0.86 | — | — | |
| SCHEMBL27611184 | 0.86 | PTGS2 (0.53) | PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6875779-B2 | Sulfonyl heteroaryl triazoles as anti-inflammatory/analgesic agents | PFIZER INC. (US) | 2005-04-05 | — | — | US | claimed |
| US-20040198735-A1 | Sulfonyl heteroaryl triazoles as anti-inflammatory/analgesic agents | SAKYA SUBAS M (US) | 2004-10-07 | — | — | US | claimed |
| EP-1273580-B1 | Sulfonyl heteroaryl triazoles as anti-inflammatory and analgesic agents | PFIZER PROD INC (US) | 2005-06-15 | — | — | EP | disclosed |
| US-6875779-B2 | Sulfonyl heteroaryl triazoles as anti-inflammatory/analgesic agents | PFIZER INC. (US) | 2005-04-05 | — | — | US | disclosed |
| US-20040198735-A1 | Sulfonyl heteroaryl triazoles as anti-inflammatory/analgesic agents | SAKYA SUBAS M (US) | 2004-10-07 | — | — | US | disclosed |
| US-6753332-B2 | CYCLOOXYGENASE INHIBITORS | PFIZER, INC. | 2004-06-22 | — | — | US | disclosed |
| US-20030119835-A1 | Sulfonyl heteroaryl triazoles as anti-inflammatory/analgesic agents | PFIZER PRODUCTS, INC. | 2003-06-26 | — | — | US | disclosed |
| EP-1273580-A1 | Sulfonyl heteroaryl triazoles as anti-inflammatory and analgesic agents | Pfizer Products Inc. (US) | 2003-01-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040198735-A1 | Sulfonyl heteroaryl triazoles as anti-inflammatory/analgesic agents | SULT2A1, SULT1A1, SULT1E1 | PTGS2 201/4885 |
| US-20030119835-A1 | Sulfonyl heteroaryl triazoles as anti-inflammatory/analgesic agents | SULT2A1, SULT1A1, SULT1E1 | PTGS2 201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.